Home>

Products

Submit Request Quote
 * Denotes Required Field.
Name:
 *
Company Name:
Phone:
Email:
 *
Message:
Request Quote
 
Out Of Stock image

Is currently out of stock, however if you enter your email address we will notify you when it comes back into stock!

Continue shopping Get Notified

Anti-CD8 alpha [MT807R1]

Anti-CD8 alpha [MT807R1]
Product Type: Therapeutics (In Vivo)
Format: Anti-CD8 alpha, MT807, rhesusized variable region, rhesus IgG1
Clone ID: [MT807R1]
RRID: AB_2716320
Common Names: Anti-CD8 alpha [MT807R1] | Depleting anti-CD8alpha (rhesus recombinant) | PR-0817 | NHP19 | aCD8alpha_MT807_rz_G1k_mamu
Target: CD8a
Reactivity: Rhesus Macaque (Macaca mulatta)
Applications: in vivo; depletion
Description:

M-T807R1: Rhesus recombinant, CDR-grafted IgG1-kappa anti-CD8alpha antibody.

How to cite this reagent

For your Materials & Methods section:

The rhesus IgG1 recombinant Anti-CD8 alpha [MT807R1] monoclonal antibody was engineered and produced by the Nonhuman Primate Reagent Resource (NIH Nonhuman Primate Reagent Resource Cat# PR-0817, RRID:AB_2716320).

For your Acknowledgements  section:

"The Anti-CD8 alpha [MT807R1] antibody used in this study was provided by the NIH Nonhuman Primate Reagent Resource (P40 OD028116)".
Modifications: None
Restrictions: No
Sponsor: ORIP

Reagent cost, which is the actual cost of production, is recovered for some reagents. Please inquire if you have questions about reagent cost recovery. Purchase order or credit card is NOW REQUIRED for cost-recovered reagents.

You are not authorized to purchase this product. Please ensure you are logged into your account.

CAN'T FIND EXACTLY WHAT YOUR RESEARCH REQUIRES?

Request a Reagent:

Would you like to see an NHP-specific antibody developed through the program? Suggest a new reagent that would benefit the NHP community.

REQUEST A REAGENT

The Nonhuman Primate Reagent Resource (NHPRR) is a nonprofit laboratory established in 1999, and supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), and Office of Research Infrastructure Programs (ORIP).

Copyright © 2004-2023